
Opinion|Videos|November 4, 2024
CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing
Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Advertisement
Video content above is prompted by the following:
- This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices.
- Please summarize the toxicities observed with CD3×CD20 BsAbs.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5
















